|
| | Tussilagone Basic information |
| Product Name: | Tussilagone | | Synonyms: | Tussilagone;L 652469;Tussilagone, 98%, from Farfarae Flos;2-Pentenoic acid, 3-methyl-, (1S,3aR,5R,7S,7aS)-1-[(1R)-1-(acetyloxy)ethyl]octahydro-4-methylene-7-(1-methylethyl)-2-oxo-1H-inden-5-yl ester, (2E)-;(1R,3aR,5R,7S,7aS)-1-(1-acetyloxyethyl)-4-methylidene-2-oxo-7-propan-2-yl-3,3a,5,6,7,7a-hexahydro-1H-inden-5-yl](E)-3-methylpent-2-enoate | | CAS: | 104012-37-5 | | MF: | C23H34O5 | | MW: | 390.51 | | EINECS: | | | Product Categories: | | | Mol File: | 104012-37-5.mol |  |
| | Tussilagone Chemical Properties |
| Boiling point | 471.3±35.0 °C(Predicted) | | density | 1.07±0.1 g/cm3 (20 ºC 760 Torr) |
| Safety Statements | 24/25 | | HS Code | 29389090 |
| | Tussilagone Usage And Synthesis |
| Chemical Properties | White crystalline powder, soluble in ether, chloroform, ethyl acetate, methanol, insoluble in water, derived from the flower bud of Asteraceae Tussilago farfara, Senecio kleinia Less root. | | Biological Activity | Tussilagone, the main active ingredient of Tussilago farfara, has anti-inflammatory properties. It ameliorates the inflammatory response of dextran sulfate sodium-induced colitis in mice. | | in vivo | Tussilagone administration (1 mg/kg and 10 mg/kg) produced decreased mortality and lung injury in CLP-activated septic mice. Augmented expression of cyclooxygenase (COX)-2 and TNF-α in pulmonary alveolar macrophages of septic mice were attenuated by tussilagone administration. |
| | Tussilagone Preparation Products And Raw materials |
|
